RT @Genmab: Our DuoBody® platform draws inspiration from nature to enable the discovery of #bispecific antibodies for the treatment of #can…
We are pleased to announce publication of preclinical data evaluating potential antitumor activity of epcoritamab in Blood Cancer Journal https://t.co/yt4xWgrJEP, helping to move #bloodcancer research forward. #CancerResearch https://t.co/n3qAO4J5da
Our DuoBody® platform draws inspiration from nature to enable the discovery of #bispecific antibodies for the treatment of #cancer. See results from preclinical evaluation of bispecific antibody epcoritamab in Blood Cancer Journal https://t.co/yt4xWgrJEP.
Genmab announces publication in Blood Cancer Journal https://t.co/yt4xWgrJEP evaluating potential of preclinical, anti-tumor activity of epcoritamab in DLBCL, FL, MCL. Congratulations to Hilma Van der Horst and team on this important publication. #CancerRe
New article: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment https://t.co/qR5bkDQX85 #FL #lymsm #hematology https://t.co/ho9P8by5fE
New article: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment https://t.co/vH2NGhgO1Z #MCL #lymsm #hematology https://t.co/qJXfgO57JG
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment https://t.co/t7q7SSj8UR
Investigators from @amsterdamumc assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from relapsed/refractory B-cell non-Hodgkin lymphoma patients. Full article 👁️ https://t.co/IKvlmKO48Y https:
RT @Lymphoma_Papers: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespe…
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. #lymphoma #lymsm https://t.co/SDdkeyk9e8
New article: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. https://t.co/tcE4fXSqnn #MCL #lymsm #hematology https://t.co/lW3NW1yNaO
RT @EgidiusLambrech: #Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irresp…
@Pharmdca Have you checked out $GMAB? https://t.co/yhELO8TE9p
RT @EgidiusLambrech: #Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irresp…
RT @EgidiusLambrech: #Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irresp…
RT @EgidiusLambrech: #Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irresp…
#Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment Blood Cancer Journal #GEN3013 #DuoBody-CD3×CD20 @Genmab $GMAB @abbvie $ABBV https://